| Biomarker ID | 687 |
| PMID | 21765474 |
| Year | 2012 |
| Biomarker | miR-139-5p; miR-1; miR-133b; miR-133a; miR-143*; miR-145*; miR-143; miR-145; miR-27b, miR-221; miR-222; miR-378; miR-204; miR-141*; miR-32; let-7b; miR-183*, miR-301b; miR-106b; miR-93; miR-25; miR-183; miR-96; miR-425; miR-663 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(miR-145):- positive regulation of transcription by RNA polymerase II; DNA-binding transcription activator activity, RNA polymerase II-specific; positive regulation of gene expression; Pancreatic adenocarcinoma pathway; positive regulation of cell population proliferation Pathways Include(miR-106b):- Gene expression (Transcription); DNA-binding transcription factor activity, RNA polymerase II-specific; RNA Polymerase II Transcription; nuclear chromatin; Generic Transcription Pathway;Pathways Include(miR-221):-homophilic cell adhesion via plasma membrane adhesion molecules; transcription by RNA polymerase II; regulation of transcription by RNA polymerase II; DNA binding; synapse |
| Experiment | group I (good prognosis) from group II (poor prognosis) |
| Type of Biomarker | Prognostic |
| Cohort | In 50 organ confined PCA patients, Group 1 consisted of clustering with normal adjacent prostate (NAP), normal lymph node and trans-urethral resection of the prostate (TURP-normal), contained 34 PCa tumors. Group 2 16 PCa tumors clustered together with samples derived from patients with advanced PCa (LN-PCa and TURP-PCa) |
| Senstivity | 91.2% |
| Specificity | 75% |
| AUC | 0.991 |
| Accuracy | 80% |
| Level Of Significance | p=0.0005 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | group II PCa tumors were strongly associated with significantly increased rate of metastases occurrence after radical prostatectomy (P=0.0001), cancer-related death (p=0.0007), ETV1 alterations (p= 0.0396) and Gleason score 46 (p=0.0272) |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | miR-139-5p, miR-1, miR-133b, miR-133a, miR-143*, miR-145*, miR-143, miR-145, miR-27b, miR-221, miR-222, miR-378, miR-204, miR-141*, miR-32, let-7b, miR-183*, miR-301b, miR-106b, miR-93, miR-25, miR-183, miR-96, miR-425, miR-663 |